Edgewise Therapeutics, Inc.
EWTX
$44.17
$0.992.29%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.64% | 24.32% | 25.58% | 27.46% | 35.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.41% | 17.36% | 20.51% | 22.98% | 28.17% |
| Operating Income | -25.41% | -17.36% | -20.51% | -22.98% | -28.17% |
| Income Before Tax | -30.87% | -20.48% | -25.40% | -26.51% | -30.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.87% | -20.48% | -25.40% | -26.51% | -30.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.87% | -20.48% | -25.40% | -26.51% | -30.05% |
| EBIT | -25.41% | -17.36% | -20.51% | -22.98% | -28.17% |
| EBITDA | -25.74% | -17.58% | -20.77% | -23.18% | -28.37% |
| EPS Basic | -18.88% | -7.28% | -12.96% | -5.73% | -1.46% |
| Normalized Basic EPS | -18.89% | -7.29% | -12.94% | -5.73% | -1.47% |
| EPS Diluted | -18.88% | -7.28% | -12.96% | -5.73% | -1.46% |
| Normalized Diluted EPS | -18.89% | -7.29% | -12.94% | -5.73% | -1.47% |
| Average Basic Shares Outstanding | 9.70% | 12.30% | 11.35% | 17.85% | 25.63% |
| Average Diluted Shares Outstanding | 9.70% | 12.30% | 11.35% | 17.85% | 25.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |